Evidence map›Paper›PMID 41201730›Full record

ArticleAnnals of nuclear medicine2026

Efficacy and safety of Lutetium-177 (

Amirreza Shamshirgaran, Pegah Sahafi, Mohammad Hadi Samadi, Michael Saeed, Hadis Mohammadzadeh Kosari, Soheila Erfani, Elahe Pirayesh, Kamran Aryana, Sara Harsini, Emran Askari

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Frailty and [Theranostics · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Amirreza ShamshirgaranUrology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Pegah SahafiNuclear Medicine Research Center, Mashhad University of Medical Sciences (MUMS), Mashhad, Iran.
Mohammad Hadi SamadiNuclear Medicine Research Center, Mashhad University of Medical Sciences (MUMS), Mashhad, Iran.
Michael SaeedNuclear Medicine Research Center, Mashhad University of Medical Sciences (MUMS), Mashhad, Iran.
Hadis Mohammadzadeh KosariNuclear Medicine Research Center, Mashhad University of Medical Sciences (MUMS), Mashhad, Iran.
Soheila ErfaniNuclear Medicine Research Center, Mashhad University of Medical Sciences (MUMS), Mashhad, Iran.
Elahe PirayeshDepartment of Nuclear Medicine, Shohadae Tajrish Medical Center, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Kamran AryanaNuclear Medicine Research Center, Mashhad University of Medical Sciences (MUMS), Mashhad, Iran.
Sara HarsiniDepartment of Medical Imaging, University of Toronto, Toronto, Ontario, Canada. sara.harsini@mail.utoronto.ca.
Emran AskariNuclear Medicine Research Center, Mashhad University of Medical Sciences (MUMS), Mashhad, Iran. AskariEM@mums.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLutetium-177 (

methodsThis study analyzed 133 mCRPC patients treated with

resultsAmong 133 patients, 17 (12.8%) exhibited a superscan pattern. The overall PSA response rate was 45.8%, (47.0% in the superscan group versus 45.6% in the non-superscan group; p = 0.485). Median PSA PFS was 8 months overall (95% CI: 5.5-10.4), with 4 months (95% CI: <1-10.5) in the superscan group and 8 months (95% CI: 5.6-10.3) in the non-superscan group (p = 0.311). Median OS was 13 months overall (95% CI: 8.6-17.3), with 6 months (95% CI: <1-18.7) in the superscan group and 14 months (95% CI: 9.3-18.6) in the non-superscan group (p = 0.052). Significant but manageable decreases were seen in platelet (PLT) and Alkaline phosphatase (ALP), and no significant changes in Hemoglobin (Hb), white blood cells (WBC), Lactate dehydrogenase (LDH), or creatinine, with no differences between superscan and non-superscan groups. Baseline hemoglobin was a significant predictor of OS (HR = 0.6, p = 0.001), while superscan pattern did not show statistical differences (HR = 1.0, p = 0.949).

conclusionThis retrospective study suggests that ¹⁷⁷Lu-PSMA-617 is a feasible and safe radioligand therapy for mCRPC patients with a superscan pattern, showing comparable PSA response rates to non-superscan patients.

Indexed as

DipeptidesHeterocyclic Compounds, 1-RingLutetiumProstatic Neoplasms, Castration-ResistantRadioisotopesSafetyAgedAged, 80 and overHumansMaleMiddle AgedNeoplasm MetastasisProstate-Specific AntigenRetrospective StudiesTreatment OutcomeDipeptidesHeterocyclic Compounds, 1-RingLutetiumLutetium-177PluvictoProstate-Specific AntigenPSMA-617Radioisotopes177Lu-PSMAProstate cancerRadioligand therapySuperscan

Identifiers

PMID41201730

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.